Clinical Epigenetics

Table 3 Univariate and multivariate analyses of risk factors for RFS

From: Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia

Variables	Univariate analysis			Multivariate analysis
Variables	No. of patients	3-year RFS (%)	P value	HR (95%CI)	P value
Gender			0.072
Male	412	76.5
Female	368	81.1
Age, years			< *0.001*	1.715(1.109–2.652)	*0.015*
< 60	692	80.3
≥ 60	88	63.0
WBC count, *10⁹/L			0.130
< 100	690	79.4
≥ 100	90	68.3
Hemoglobin, g/L			0.617
< 100	534	78.7
≥ 100	246	78.7
Platelet count, *10⁹/L			0.520
< 100	632	79.3
≥ 100	148	76.0
Karyotype^a			*0.012*		*0.024*
Favorable	96	90.0		1
Intermediate	575	77.8		2.396(1.202–4.775)
Adverse	80	67.8		2.953(1.323–6.591)
2017 ELN			*0.005*
Favorable	344	84.4
Intermediate	216	73.5
Adverse	220	72.4
HSCT			*0.014*	0.769(0.533–1.108)	0.158
Yes	468	81.4
No	312	74.2
DMRGM	227	72.0	*0.002*	1.467(1.030–2.090)	*0.034*
FLT3-ITD^Mut	131	78.2	0.545
NPM1^Mut	140	72.7	*0.027*	0.966(0.622–1.498)	0.876
DNMT3A^Mut	96	63.4	< *0.001*
CEBPA^bm	105	88.2	*0.016*	0.530(0.295–0.952)	*0.034*
NRAS^Mut	92	79.0	0.915
TET2^Mut	75	68.0	*0.023*
KIT^Mut	81	76.1	0.373
WT1^Mut	71	80.4	0.995
IDH2^Mut	71	73.5	0.451
FLT3-TKD^Mut	65	76.4	0.813
RUNX1^Mut	58	73.0	0.355
GATA2^Mut	53	85.3	0.255
KRAS^Mut	44	72.5	0.701
ASXL1^Mut	47	84.4	0.148
PTPN11^Mut	42	70.6	*0.048*	1.610(0.878–2.950)	0.124
JAK^Mut	42	73.1	0.526
IDH1^Mut	39	80.0	0.979

RFS: relapse-free survival; WBC: white blood cell; 2017 ELN: 2017 European Leukemia Network; HSCT: hematopoietic stem cell transplantation; DMRGM: DNA methylation regulatory gene mutations. A P value of less than 0.05 is indicated in italics and bold
^aKaryotype data is unknown form 29 patients

Back to article page

ISSN: 1868-7083

Contact us

Submission enquiries: avalyn.villar@springernature.com
General enquiries: info@biomedcentral.com